Ex-FDA Chief Calls for Fast 'Breakthrough' Path

Share this article:
Mark McClellan
Mark McClellan

Legislation to speed FDA approval of breakthrough drugs is being supported by both former FDA commissioner Mark McClellan, now a Brookings Institution senior fellow, and Friends of Cancer Research chairperson Ellen Sigal.

“When a new drug or drug combination shows extreme activity very early,” they wrote in The Hill's Congress Blog, “new approaches are needed that focus on the most efficient mechanisms to get a potential medical breakthrough to the relevant patients.”

McClellan and Sigal speak approvingly of bipartisan legislation introduced in the Senate to establish a breakthrough product designation that they say would (1) reduce the total development time and cost of the most promising breakthrough treatments, and (2) minimize the number of patients that would be given a control regimen or a currently available treatment that doesn't work very well.

Upon designation, the two explain, FDA and the drug sponsor would engage in intensive interactions to collaboratively construct and agree upon a drug development strategy.
Share this article:

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"